1149 related articles for article (PubMed ID: 31064820)
41. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes.
Wang JJ; Zhang YT; Tseng YJ; Zhang J
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):360-365. PubMed ID: 31126802
[TBL] [Abstract][Full Text] [Related]
42. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis.
Zhang M; Chi X; Qu N; Wang C
Biochem Biophys Res Commun; 2018 Apr; 499(1):66-70. PubMed ID: 29555473
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR.
Nie H; Song C; Wang D; Cui S; Ren T; Cao Z; Liu Q; Chen Z; Chen X; Zhou Y
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3087-3094. PubMed ID: 28951211
[TBL] [Abstract][Full Text] [Related]
44. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
45. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt.
Jia Y; Wu C; Kim J; Kim B; Lee SJ
J Nutr Biochem; 2016 Feb; 28():9-18. PubMed ID: 26878778
[TBL] [Abstract][Full Text] [Related]
46. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.
Jalilian A; Golmohammadi T; Meshkani R; Koushki M; Eivazi N; Khorzoughi RB; Fard SRH; Paknejad M
Mol Biol Rep; 2021 Feb; 48(2):1359-1370. PubMed ID: 33580458
[TBL] [Abstract][Full Text] [Related]
48. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
49. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease.
Xu M; Zheng XM; Jiang F; Qiu WQ
J Cell Biochem; 2018 Jul; 119(7):5864-5874. PubMed ID: 29575055
[TBL] [Abstract][Full Text] [Related]
50. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
51. CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease.
Yuan X; Li Y; Wen S; Xu C; Wang C; He Y; Zhou L
Lipids Health Dis; 2022 Nov; 21(1):127. PubMed ID: 36443854
[TBL] [Abstract][Full Text] [Related]
52. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
[TBL] [Abstract][Full Text] [Related]
53. miR-32-5p induces hepatic steatosis and hyperlipidemia by triggering de novo lipogenesis.
Wang YD; Wu LL; Mai YN; Wang K; Tang Y; Wang QY; Li JY; Jiang LY; Liao ZZ; Hu C; Wang YY; Liu JJ; Liu JH; Xiao XH
Metabolism; 2023 Sep; 146():155660. PubMed ID: 37451670
[TBL] [Abstract][Full Text] [Related]
54. MiR-22 modulates the expression of lipogenesis-related genes and promotes hepatic steatosis in vitro.
Yang Z; Qin W; Huo J; Zhuo Q; Wang J; Wang L
FEBS Open Bio; 2021 Jan; 11(1):322-332. PubMed ID: 33159388
[TBL] [Abstract][Full Text] [Related]
55. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
56. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
57. Pin1 Exacerbates Non-Alcoholic Fatty Liver Disease by Enhancing Its Activity through Binding to ACC1.
Jin Y; Shangguan Z; Pang J; Chen Y; Lin S; Liu H
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892011
[TBL] [Abstract][Full Text] [Related]
58. Obesity-Induced Upregulation of ZBTB7A Promotes Lipid Accumulation through SREBP1.
Zhou JP; Ren YD; Xu QY; Song Y; Zhou F; Chen MY; Liu JJ; Chen LG; Pan JS
Biomed Res Int; 2020; 2020():4087928. PubMed ID: 31998789
[TBL] [Abstract][Full Text] [Related]
59. miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.
Ali O; Darwish HA; Eldeib KM; Abdel Azim SA
Oxid Med Cell Longev; 2018; 2018():8515343. PubMed ID: 30402207
[TBL] [Abstract][Full Text] [Related]
60. Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet.
Zheng F; Cai Y
Lipids Health Dis; 2019 Jan; 18(1):6. PubMed ID: 30611282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
